

Tchaikapharma High Quality Medicines Inc.
Interim statement of Financial status
as of 30 of September 2024

	30.09.2024	31.12.2023
	<i>BGN'000</i>	<i>BGN'000</i>
ASSETS		
Non-current assets		
Property, plant and equipment	34 465	33 083
Intangible assets	3 567	3 560
Investments in subsidiaries	69	19
Trade receivables	4 978	4 978
Total non-current assets	43 079	41 640
Current assets		
Inventories	15 298	14 303
Trade and other receivables	66 749	66 490
Current corporate income tax	-	12
Cash and cash equivalents	111	60
Total current assets	82 158	80 865
Total assets	125 237	122 505
LIABILITIES		
Equity		
Share capital	91 800	84 500
Reserves	13 147	12 800
Retained earnings	4 404	7 707
Total	109 351	105 007
Non-current liabilities		
Long-term loans	659	879
Deferred tax liabilities	1 113	1 113
Retirement benefit obligations	173	197
Total non-current liabilities	1 945	2 189
Current liabilities		
Trade and other liabilities	3 456	4 768
Short-term loans	9 783	9 791
Current portion of long-term loans	282	507
Other tax liabilities	420	243
Total current liabilities	13 941	15 309
Total liabilities	15 886	17 498
Total equity and liabilities	125 237	122 505

Date of preparation: 23.10.2024

Sofia

Prepared by:.....

/ P. Moneva /

Executive Director:.....

/B. Georgiev/

Tchaikapharma High Quality Medicines Inc.
Interim statement of comprehensive income
as of 30 of September 2024

	30.09.2024	30.09.2023
	<i>BGN'000</i>	<i>BGN'000</i>
Revenue	40 414	39 076
Other income	182	64
Total income	40 596	39 140
Carrying amount of goods sold	(1 953)	(775)
Changes in inventories of finished products and work in progress	318	(509)
Materials and services	(24 712)	(24 922)
Personnel expenses	(6 664)	(4 773)
Depreciation / amortisation expenses	(1 877)	(2 198)
Other expenses	(434)	(775)
Finance income	40	46
Finance costs	(550)	(480)
Total expenses	(35 832)	(34 386)
Profit before taxation	4 764	4 754
Corporate income tax expense	(420)	(350)
Profit/Loss for the period	4 344	4 404
Total comprehensive income for the period	4 344	4 404
Earnings per share / in BGN per 1 share /	0.05	0.05

Date of preparation: 23.10.2024

Sofia

Prepared by:.....

/ P. Moneva /

Executive Director:.....

/B. Georgiev/

Tchaikapharma High Quality Medicines Inc.
Interim cash flow statement
as of 30 of September 2024

	30.09.2024	30.09.2023
	<i>BGN'000</i>	<i>BGN'000</i>
Cash flows from operating activities		
Proceeds from sale of finished products, goods and services	30 227	24 559
Payments to suppliers of materials, goods and services	(15 642)	(13 077)
Payments to personnel	(6 832)	(4 462)
Foreign currency exchange gains/losses	(26)	(20)
Payments of interest and dividends	(408)	(323)
Other proceeds / payments	(4 704)	(4 359)
Net cash flows	2 615	2 318
Cash flows from investing activities		
Payments on non-current assets acquired	(1 687)	(1 605)
Other post/payments for investment activity	(50)	-
Net cash flows	(1 737)	(1 605)
Cash flows from financial activities		
Proceeds from loans	438	357
Payments on loans	(446)	(360)
Payment of interest, dividends	(428)	(375)
Payments on finance lease	(391)	(391)
Net cash flows	(827)	(769)
<hr/>		
Change in cash and cash equivalents	51	(56)
Cash and cash equivalents at the beginning of the period	60	126
Cash and cash equivalents at the end of the period	111	70

Date of preparation: 23.10.2024

Sofia


Prepared by:.....
 / P. Moneva /


Executive
 Director:.....
 /B. Georgiev /

Tchaikapharma High Quality Medicines Inc.
Interim statement on changes in equity
as of 30 of September 2024

	Registered (share) capital <i>BGN'000</i>	Revaluation reserves <i>BGN'000</i>	Other reserves <i>BGN'000</i>	Retained earnings / loss <i>BGN'000</i>	Total equity <i>BGN'000</i>
Balance as of 01.01.2023	84 500	4 351	8 147	4 591	101 589
Profit/loss for the period				3 400	3 400
Other comprehensive income		18			18
Including from tax effect of the revaluation of property, plant and equipment					
Total comprehensive income		18		3 400	3 400
Issue of shares by the owners			284	(284)	
Dividends accrued			284	(284)	
Tantiemmes accrued					
Profit transferred to reserves					
Total amount of income and expenses recognised during the period					
Balance as of 31.12.2023	84 500	4 369	8 431	7 707	105 007
Balance as of 01.01.2024	84 500	4 369	8 431	7 707	105 007
Profit/loss for the period				4 344	4 344
Other comprehensive income					
Total comprehensive income				4 344	4 344
Issue of shares by the owners	7 300		347	(7 647)	
Total amount of income and expenses recognised during the period	7 300		347	(7 647)	
Balance as of 30.09.2024	91 800	4 369	8 778	4 404	109 351

Date of preparation: 23.10.2024
Sofia

Prepared by:.....

/P. Moneva/

Executive Director:.....

/B. Georgiev/